 companion strength
updat model follow compani result
featur continu robust growth companion anim busi
off-set headwind livestock tweak ep estim base
higher companion anim sale driven simparica trio launch
pt remain continu view best-in-class anim health
compani maintain hold rate stock base
view rel balanc risk/reward said see investor
pay themat appeal solid execut market leadership
report ep estim consensu
total revenu close estim higher companion anim
sale particularli us off-set lower livestock sale us ou gross
margin strong vs model aid fx product mix
price contribut upsid ep estim
takeaway quarter
view key takeaway plan launch simparica trio
europ canada us earli assum fda
approv decis expect manag anticip
simparica trio could gener increment sale franchis
assum cannib simparica livestock sale
impact continu weak us beef dairi sector
on-going effect african swine fever asf china continu
anticip medium long-term benefit increas product pork
protein yet seen product increas signific
lower revenu base lower
sale us intern livestock rais
revenu base primarili higher sale us
intern companion anim driven continu strong growth
dermatolog franchis simparica trio launch partial off-set lower
sale livestock also increas sg estim reflect greater
invest support launch recent acquisit new ep
ep
tr target
page
expens attribut non-control zoeti inc
page
expens attribut non-control zoeti inc
page
manufacturing/human changeu manufacturing/human oper revenueu manufacturing/human profitexist apoquel gross marginexist apoquel gross zoeti inc
page
manufacturing/human changeu manufacturing/human oper revenueu manufacturing/human profitexist apoquel gross marginexist apoquel gross zoeti inc
zoeti largest anim health compani world sale compani strong
perform sinc spun nr consist above-market revenu
growth signific margin expans well-diversifi revenu base geograph
across companion food anim segment compani expand veterinari
diagnost market acquisit abaxi
despit hold rate stock view best-in-class anim health compani
attract combin sustain organ growth diversifi portfolio low-risk strategi
cash-pay model leverag infrastructur expect base busi drive solid revenu
earn growth next year may supplement select busi
develop new launch said believ attribut larg understood
marketplac would prefer attract entri point thu rate share hold
valuat risk
pt assum stock trade ebitda similar
current multipl ebitda downsid risk includ lower growth livestock
companion segment lower growth abaxi lower sale key product apoquel cytopoint
simparica consolid custom and/or competitor global econom downturn advers
fx trend upsid risk includ higher growth livestock companion abaxi higher sale
apoquel cytopoint simparica greater contribut new product
compani mention note
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
